PE20021073A1 - Derivados de cromano 2,6-sustituidos utiles como agonistas adrenoreceptores beta-3 - Google Patents

Derivados de cromano 2,6-sustituidos utiles como agonistas adrenoreceptores beta-3

Info

Publication number
PE20021073A1
PE20021073A1 PE2002000337A PE2002000337A PE20021073A1 PE 20021073 A1 PE20021073 A1 PE 20021073A1 PE 2002000337 A PE2002000337 A PE 2002000337A PE 2002000337 A PE2002000337 A PE 2002000337A PE 20021073 A1 PE20021073 A1 PE 20021073A1
Authority
PE
Peru
Prior art keywords
alkyl
hydroxy
methyl
members
pyridinyl
Prior art date
Application number
PE2002000337A
Other languages
English (en)
Inventor
Connor Stephen J O'
Gaetan H Ladouceur
Ann-Marie Campbell
Robert Dally
Holia N Hatoum-Mokdad
Wendy Lee
Derek B Lowe
Ning Qi
Ming Wang
Roger A Smith
Quanrong Shen
Tatiana E Shelekhin
Steven R Magnuson
Qingjie Liu
Uday Khire
Jacques Dumas
Miao Dai
William H Bullock
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of PE20021073A1 publication Critical patent/PE20021073A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A DERIVADOS DE CROMANO DE FORMULA I DONDE R ES HIDROXI, OXO, HALO, CIANO, NITRO, ALQUILO C1-C10, HALOALQUILO C1-C10, CF3, SR1, NR1R1, OCOR2, COR2, ENTRE OTROS; R1 ES H, (CH2)d-O-(CH2)dR5, ALQUILO C1-C10, HIDROXI, HALO, CO2-ALQUILO C1-C4, ALCOXI C1-C10, ENTRE OTROS; R2 ES R1, OR1, NR1R1, NHSObFENILO, NHSOb-ALQUILO C1-C10; R3 ES H, ALQUILO C1-C10, COR2; R4 ES H, ALQUILO C1-C10, ALQUILFENILO C1-C10, ALQUIL-PIRIDILO C1-C10; R5 ES H, COOH; R6 ES H, ALQUILO C1-C10, ALQUILO C1-C10-SOb-ALQUILO C1-C10;Ar ES FENILO OPCIONALMENTE SUSTITUIDO CON UN HETEROCICLO DE 5-6 MIEMBROS, HETEROCICLO DE 5-6 MIEMBROS; Y ES HALO, NO2, R6, SR1, SObFENILO-CO2R1, (CO-NR4-(R4)2)e-CO2R1, R4 PUEDE FORMAR UN ANILLO ESPIRO DE 3-6 MIEMBROS; R7 ES FENILO, HETEROARILO CON 3-6 MIEMBROS; R8 ES ALQUILO C1-C6 OPCIONALMENTE SUSTITUIDO CON ALCOXI C1-C4, N(CH3)2, CICLOALQUILO C3-C6, FENILO, ENTRE OTROS; R9 ES CICLOALQUILO C3-C6, TIENILO, PIRIDILO, PIRAZOLILO, ENTRE OTROS; a ES 0-5; b ES 0-2; d ES 1-3; e ES 1-2. SON COMPUESTOS PREFERIDOS (1R)-2-({[(2R)-6-YODO-3,4-DIHIDRO-2H-CROMEN-2-IL]METIL}AMINO)-1-(3-PIRIDINIL)ETANOL-4-[(2R)-2-({[(2R)-2-HIDROXI-2-(3-PIRIDINIL)ETIL]AMINO}METIL)-3,4-DIHIDIRO-2H-CROMEN-6-IL]-2-FENOXI)-BENZOICO, ACIDO-5-[(2R)-2-({[(2R)-2-HIDROXI-2-(3-PIRIDINIL)ETIL]AMINO}METIL)-3,4-DIHIDRO-2H-CROMEN-6-IL]-4'-METIL-1,1'-BIFENIL-2-CARBOXILICO, ENTRE OTROS. LOS COMPUESTOS SON AGONISTAS ADRENERGICOS BETA-3 Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE OBESIDAD, DIABETES, DESORDENES GASTROINTESTINALES
PE2002000337A 2001-04-23 2002-04-23 Derivados de cromano 2,6-sustituidos utiles como agonistas adrenoreceptores beta-3 PE20021073A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28571901P 2001-04-23 2001-04-23
US32451801P 2001-09-26 2001-09-26

Publications (1)

Publication Number Publication Date
PE20021073A1 true PE20021073A1 (es) 2002-12-12

Family

ID=26963345

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000337A PE20021073A1 (es) 2001-04-23 2002-04-23 Derivados de cromano 2,6-sustituidos utiles como agonistas adrenoreceptores beta-3

Country Status (9)

Country Link
US (3) US6660752B2 (es)
EP (1) EP1389202B1 (es)
JP (1) JP2004532227A (es)
AR (1) AR035858A1 (es)
DE (1) DE60201437T2 (es)
DO (1) DOP2002000385A (es)
ES (1) ES2230487T3 (es)
PE (1) PE20021073A1 (es)
WO (1) WO2002085891A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
KR100823805B1 (ko) * 2004-05-05 2008-04-21 에프. 호프만-라 로슈 아게 5-ｈｔ6 수용체, 5-ｈｔ2ａ 수용체 또는 둘다를 조절하기에유용한 아릴설포닐 벤조다이옥산
EP1831203A1 (en) 2004-12-21 2007-09-12 F. Hoffmann-Roche AG Chroman derivatives and uses thereof in the treatment of cns disorders
MX2007007558A (es) * 2004-12-21 2007-07-24 Hoffmann La Roche Derivados de tetralina y de indano y usos de los mismos.
CA2592001A1 (en) * 2004-12-21 2006-06-29 F. Hoffmann-La Roche Ag Chroman derivatives and their use as 5-ht receptor ligands
ATE448216T1 (de) * 2004-12-21 2009-11-15 Hoffmann La Roche Tetralin- und indanderivate und anwendungen davon
MX2007007482A (es) * 2004-12-21 2007-07-20 Hoffmann La Roche Derivados de tetralina e indano y usos de los mismos como antagonistas de 5-ht.
EP1856126A2 (en) 2005-02-17 2007-11-21 Wyeth a Corporation of the State of Delaware Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives
BRPI0618206A2 (pt) * 2005-11-03 2011-08-23 Hoffmann La Roche arilsulfonil cromanos como inibidores de 5-ht6, bem como composição farmacêutica, uso e processo para produção dos mesmos
GB0526252D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
EP2402320A1 (en) 2006-03-31 2012-01-04 Novartis AG Anorectic agents
BRPI0713502A2 (pt) * 2006-06-20 2012-03-13 F. Hoffmann-La Roche Ag derivados de tetralina de arilsulfonamidil e empregos destes
CA2654822A1 (en) * 2006-06-20 2007-12-27 F. Hoffmann-La Roche Ag Arylsulfonyl naphthalene derivatives and uses thereof
CN101472884A (zh) * 2006-06-20 2009-07-01 弗·哈夫曼-拉罗切有限公司 1,2,3,4-四氢化萘和茚满衍生物及其用途
SI2750677T1 (sl) 2011-08-30 2017-10-30 Chdi Foundation, Inc. Inhibitorji kinurenin-3-monooksigenaze, farmacevtski sestavki in postopki njihove uporabe
UA122520C2 (uk) 2013-01-09 2020-11-25 Басф Агро Б.В. Кристалічна форма 2-[4-(4-хлорфенокси)-2-(трифторметил)феніл]-1-(1,2,4-триазол-1-іл)пропан-2-олу, агрохімічна композиція, застосування та спосіб боротьби зі шкідливими грибами
US9790231B2 (en) * 2013-06-24 2017-10-17 Lupin Limited Chromane and chromene derivatives and their use as CRAC modulators
WO2015003908A1 (en) 2013-07-08 2015-01-15 Basf Se Compositions comprising a triazole compound and a biopesticide
EA037646B1 (ru) * 2013-12-12 2021-04-27 Басф Агро Б.В. Способ получения замещенных триазолов
EA201892682A1 (ru) 2014-06-25 2019-04-30 Басф Агро Б.В. Пестицидные композиции
DK3166932T3 (en) 2014-07-08 2018-10-01 Basf Agro Bv PROCEDURE FOR PREPARING SUBSTITUTED OXIRANES AND TRIAZOLES
CN106715421A (zh) 2014-07-17 2017-05-24 Chdi基金会股份有限公司 用于治疗hiv相关病症的方法和组合物
PL3214937T3 (pl) 2014-11-07 2024-10-14 Basf Se Mieszaniny szkodnikobójcze
DK3294700T3 (da) 2015-05-08 2020-04-14 Basf Agro Bv Fremgangsmåde til fremstilling af limonen-4-ol
EP3294720B1 (en) 2015-05-08 2020-12-02 BASF Agro B.V. A process for the preparation of terpinolene epoxide
WO2017095723A1 (en) * 2015-11-30 2017-06-08 Merck Sharp & Dohme Corp. Aryl acylsulfonamides as blt1 antagonists
WO2017095722A1 (en) * 2015-11-30 2017-06-08 Merck Sharp & Dohme Corp. Aryl acylsulfonamides as blt1 antagonists
WO2017157920A1 (en) 2016-03-16 2017-09-21 Basf Se Use of tetrazolinones for combating resistant phytopathogenic fungi on fruits
RU2754614C2 (ru) 2016-03-16 2021-09-03 Басф Се Применение тетразолинонов для борьбы с устойчивыми фитопатогенными грибами на злаковых культурах
BR112018068705B1 (pt) 2016-03-16 2022-09-06 Basf Se Método para controlar fungos fitopatogênicos
EP3472139B1 (en) 2016-06-15 2021-04-07 BASF Agro B.V. Process for the epoxidation of a tetrasubstituted alkene
ES2833202T3 (es) 2016-06-15 2021-06-14 Basf Agro Bv Procedimiento para la epoxidación de un alqueno tetrasustituido
GB201803394D0 (en) * 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
WO2021101927A1 (en) 2019-11-18 2021-05-27 Vanderbilt University Wdr5-myc inhibitors
WO2024040267A2 (en) * 2022-08-19 2024-02-22 Mitokinin, Inc. Direct synthesis of n-(3-substituted-chroman-4-yl)-7h- pyrrolo[2,3-d]pyrimidin-4-amines and derivatives thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3706764A (en) 1969-04-16 1972-12-19 Yoshitomi Pharmaceutical Phenethylaminomethyl-chromanones and- thiochromanones
US3803176A (en) 1969-05-09 1974-04-09 Novo Terapeutisk Labor As Sulfonylurea derivatives
GB1499323A (en) 1974-03-22 1978-02-01 Fisons Ltd 6-substituted chromones and chromanones
US4474788A (en) 1981-11-12 1984-10-02 Fisons Plc Anti-SRSA quinoline carboxylic acid derivatives
EP0091749A3 (en) 1982-04-08 1984-12-05 Beecham Group Plc Ethanolamine derivatives, process for their preparation and pharmaceutical compositions containing them
ZA844519B (en) 1983-06-24 1985-02-27 Hoffmann La Roche Dihydrobenzopyran derivatives
US4654362A (en) 1983-12-05 1987-03-31 Janssen Pharmaceutica, N.V. Derivatives of 2,2'-iminobisethanol
DE3411992A1 (de) 1984-03-31 1985-10-10 Bayer Ag, 5090 Leverkusen Substituierte 4-hydroxy-benzopyrane, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
US4727877A (en) * 1984-12-18 1988-03-01 Medtronic, Inc. Method and apparatus for low energy endocardial defibrillation
GB8801306D0 (en) 1988-01-21 1988-02-17 Ici Plc Chemical compounds
US5117824A (en) * 1990-11-14 1992-06-02 Medtronic, Inc. Apparatus for monitoring electrical physiologic signals
US5163427A (en) * 1990-11-14 1992-11-17 Medtronic, Inc. Apparatus for delivering single and multiple cardioversion and defibrillation pulses
US5129392A (en) * 1990-12-20 1992-07-14 Medtronic, Inc. Apparatus for automatically inducing fibrillation
FR2695387B1 (fr) 1992-09-09 1994-10-21 Adir Nouveaux composés benzopyraniques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US5451677A (en) 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
BR9406823A (pt) 1993-06-14 1996-03-26 Pfizer Aminas secundárias e agentes anti-diabéticos e antiobesidade
GB9405019D0 (en) 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
US5541197A (en) 1994-04-26 1996-07-30 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
US5561142A (en) 1994-04-26 1996-10-01 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
IL113410A (en) 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
US5516917A (en) 1994-06-08 1996-05-14 G. D. Searle & Co. Leukotriene B4 antagonists
JPH08198866A (ja) 1995-01-20 1996-08-06 Tokyo Tanabe Co Ltd 新規２−アミノ−１−フェニルエタノール化合物
US5674254A (en) * 1995-05-22 1997-10-07 Vitatron Medical, B.V. Cardiac pacemaker system and method for determining a measure of pacing threshold without incurring loss of capture
US5663194A (en) 1995-07-25 1997-09-02 Mewshaw; Richard E. Chroman-2-ylmethylamino derivatives
ZA967892B (en) 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
FR2746395B1 (fr) * 1996-03-22 1998-04-17 Adir Nouveaux derives d'arylethanolamine et d'aryloxypropanolamine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP3708624B2 (ja) 1996-03-27 2005-10-19 キッセイ薬品工業株式会社 ３，４−ジ置換フェニルエタノールアミノテトラリンカルボン酸誘導体
EP0801060A1 (en) 1996-04-09 1997-10-15 Pfizer Inc. Heterocyclic Beta-3 Adrenergenic Agonists
CA2257206A1 (en) 1996-06-07 1997-12-11 Gui-Bai Liang Oxadiazole benzenesulfonamides as selective .beta.3 agonists for the treatment of diabetes and obesity
KR20000070568A (ko) 1997-01-28 2000-11-25 폴락 돈나 엘. 당뇨병 및 비만 치료를 위한 β3 효능제로서의 티아졸 벤젠설폰아미드
US5741312A (en) * 1997-03-12 1998-04-21 Vitatron Medical, B.V. Pacemaker system and method with improved capture detection and threshold search
US6469031B1 (en) * 1998-12-18 2002-10-22 Bayer Corporation Carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists
US6051586A (en) 1997-12-19 2000-04-18 Bayer Corporation Sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists
ID26524A (id) * 1997-12-19 2001-01-11 Bayer Ag Turunan-turunan kroman tersubstitusi karboksil bermanfaat sebagai agonis beta-3 adrenoreseptor
US6052621A (en) * 1998-01-27 2000-04-18 Vitatron Medical B.V. System and method for inducing tachycardia
GB9812709D0 (en) 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
WO2000069517A1 (en) * 1999-05-12 2000-11-23 Medtronic, Inc. Monitoring apparatus using wavelet transforms for the analysis of heart rhythms
US6647292B1 (en) * 2000-09-18 2003-11-11 Cameron Health Unitary subcutaneous only implantable cardioverter-defibrillator and optional pacer
US6675042B2 (en) * 2002-04-15 2004-01-06 Charles D. Swerdlow Defibrillation shock strength determination technology

Also Published As

Publication number Publication date
JP2004532227A (ja) 2004-10-21
EP1389202B1 (en) 2004-09-29
EP1389202A1 (en) 2004-02-18
AR035858A1 (es) 2004-07-21
US6919371B2 (en) 2005-07-19
DE60201437D1 (de) 2004-11-04
US6660752B2 (en) 2003-12-09
DOP2002000385A (es) 2004-01-31
US20030078260A1 (en) 2003-04-24
US20040072828A1 (en) 2004-04-15
WO2002085891A1 (en) 2002-10-31
ES2230487T3 (es) 2005-05-01
US20050215594A1 (en) 2005-09-29
DE60201437T2 (de) 2005-12-15

Similar Documents

Publication Publication Date Title
PE20021073A1 (es) Derivados de cromano 2,6-sustituidos utiles como agonistas adrenoreceptores beta-3
PE20040164A1 (es) Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas
PE20040650A1 (es) Moduladores del receptor de glucocorticoides
AR044152A1 (es) Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
PE20040775A1 (es) DERIVADOS DE INDOL COMO AGONISTAS DE ADRENORECEPTORES ß2
RU2008127312A (ru) Мезилатное пролекарство леводопы, его композиции и применение
PE69299A1 (es) Compuestos calciliticos
PE20021014A1 (es) Derivados de glutaramida sustituida con n-fenpropilciclopentilo como inhibidores de nep para fsad
YU96103A (sh) Novi derivati indola sa afinitetom za 5-ht6 receptor
AR041260A1 (es) Piperazinas sustituidas por heterociclos para el tratamiento de la esquizofrenia
AR058546A1 (es) Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1
DE60335869D1 (de) 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
PE20070321A1 (es) Compuestos heterociclicos como inhibidores de proteasas
CY1109493T1 (el) Παραγωγα οξαζολιου ως παραγοντες η3 υποδοχεα ισταμινης, παρασκευη και θεραπευτικες χρησεις
HRP20040977B1 (hr) Derivati n-[fenil(piperidin-2-il)metil]benzamida,postupak njihovog pripravljanja i primjena istih u terapiji
PE20030925A1 (es) Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico
PE20040907A1 (es) Derivados de anilinopirazol
ATE440833T1 (de) Antithrombotische diamide
PE20030718A1 (es) Lactamas como antagonistas de taquiquininas
RU2011112684A (ru) АГЕНТ, СПОСОБСТВУЮЩИЙ РОСТУ ВОЛОС, СОДЕРЖАЩИЙ В КАЧЕСТВЕ АКТИВНОГО ИНГРЕДИЕНТА ПРОИЗВОДНОЕ 15,15-ДИФТОРПРОСТАГЛАНДИНА F2α
PE20040122A1 (es) Derivados de aminometil cromano di-sustituido como agonistas de beta-3-adreno-receptores
BRPI0417858A (pt) composto, composição farmacêutica, e, uso de uma composição farmacêutica
AR040033A1 (es) Metodos para el tratamiento de trastornos de dolor gastrointestinal y genitourinario
PE20070069A1 (es) Piperazin-piperidinas como antagonistas y agonistas del receptor 5-ht1a
DE602004026558D1 (de) Selektive nichtsteroidale glucocorticoid-rezeptor- modulatoren

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed